A few months ago the Food and Drug Administration (FDA) made waves by approving a cannabis-based medication for the first time ever. And now that medication is finally available to the public.
Epidiolex is now available to be prescribed in all 50 states. The medication is meant for people who suffer from either Dravet syndrome or Lennox-Gastaut syndrome, both of which are conditions that cause seizures starting at an early age. Both of these conditions are known to be resistant to traditional forms of seizure medication, but have been managed and controlled through administration of cannabidiol (CBD). Epidiolex is 98 percent extracted CBD.
Many cannabis advocates have celebrated Epidiolex. By becoming the first cannabis-based medication approved by the FDA, it meant a federal government agency was acknowledging that a compound in cannabis has documented medical benefits. This would seemingly disprove the federal government's own classification of the drug as a Schedule I controlled substance, meaning it has no medical value whatsoever, a distinction it shares with heroin.
It's not quite clear what the future ramifications will be from Epidiolex's success, but many other companies are exploring creating medications that use CBD. So once again even Big Business can see the benefits of marijuana while the government cannot.